A BILL 
To mitigate drug shortages and provide incentives for main-
taining, expanding, and relocating the manufacturing of 
active pharmaceutical ingredients, excipients, medical di-
agnostic devices, pharmaceuticals, and personal protec-
tive equipment in the United States, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
2 
•HR 3927 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Manufacturing API, 
2
Drugs, and Excipients in America Act’’ or the ‘‘MADE 
3
in America Act’’. 
4
SEC. 2. TABLE OF CONTENTS. 
5
The table of contents of this Act is as follows: 
6
Sec. 1. Short title. 
Sec. 2. Table of contents. 
TITLE I—HEALTH PROVISIONS 
Sec. 101. Report to Congress on barriers to domestic manufacturing of medical 
products. 
Sec. 102. Enhance intra-agency coordination and public health assessment with 
regard to compliance activities. 
Sec. 103. Reporting of mutual recognition agreements for inspections and re-
view activities. 
Sec. 104. Enhancing transparency of drug facility inspection timelines. 
Sec. 105. Advanced manufacturing technologies program. 
TITLE II—TAX INCENTIVES TO INCREASE DOMESTIC 
PHARMACEUTICAL AND MEDICAL DEVICE PRODUCTION 
Sec. 201. Credit for pharmaceutical and medical device production activities in 
distressed zones. 
TITLE I—HEALTH PROVISIONS 
7
SEC. 101. REPORT TO CONGRESS ON BARRIERS TO DOMES-
8
TIC MANUFACTURING OF MEDICAL PROD-
9
UCTS. 
10
(a) REPORT.—Not later than 6 months after the date 
11
of enactment of this Act, the Secretary of Health and 
12
Human Services, the Secretary of the Treasury, the Sec-
13
retary of Commerce, and the United States Trade Rep-
14
resentative (collectively referred to in this section as the 
15
‘‘Secretaries’’) shall submit to the Committee on Health, 
16
Education, Labor, and Pensions of the Senate and the 
17
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
3 
•HR 3927 IH
Committee on Energy and Commerce of the House of 
1
Representatives a report on barriers to domestic manufac-
2
turing of active pharmaceutical ingredients, finished drug 
3
products, and devices that are imported from outside of 
4
the United States. 
5
(b) CONTENTS.—Such report shall— 
6
(1) identify factors that limit or otherwise dis-
7
courage the domestic manufacturing of active phar-
8
maceutical ingredients, drugs, and devices that are 
9
currently imported from outside of the United 
10
States, including any Federal, State, local, or Tribal 
11
laws that hinder domestic manufacturing opportuni-
12
ties; and 
13
(2) recommend specific strategies to overcome 
14
the challenges identified under paragraph (1), in-
15
cluding strategies— 
16
(A) to develop effective incentives for do-
17
mestic manufacturing; and 
18
(B) to make changes to laws or regulations 
19
that hinder domestic manufacturing opportuni-
20
ties. 
21
(c) CONSULTATION.—In preparing the report under 
22
subsection (a), the Secretaries shall consult with— 
23
(1) the Food and Drug Administration, the 
24
Centers for Medicare & Medicaid Services, the De-
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
4 
•HR 3927 IH
partment of Defense, the Department of State, the 
1
Department of Veterans Affairs, the Department of 
2
Justice, and any other Federal agencies as appro-
3
priate; and 
4
(2) relevant stakeholders, including drug, de-
5
vice, and active pharmaceutical ingredient manufac-
6
turers, and other entities, as appropriate. 
7
(d) DEFINITION.—In this section, the term ‘‘active 
8
pharmaceutical ingredient’’ has the meaning given to such 
9
term in section 207.1 of title 21, Code of Federal Regula-
10
tions (or any successor regulations). 
11
(e) PUBLICATION.—The Secretary shall make the re-
12
port under subsection (a) available on the public website 
13
of the Department of Health and Human Services. 
14
SEC. 102. ENHANCE INTRA-AGENCY COORDINATION AND 
15
PUBLIC HEALTH ASSESSMENT WITH REGARD 
16
TO COMPLIANCE ACTIVITIES. 
17
(a) COORDINATION.—Section 506D of the Federal 
18
Food, Drug, and Cosmetic Act (21 U.S.C. 356d) is 
19
amended by adding at the end the following: 
20
‘‘(g) COORDINATION.—The Secretary shall ensure 
21
timely and effective internal coordination and alignment 
22
among the field investigators of the Food and Drug Ad-
23
ministration and the staff of the Center for Drug Evalua-
24
tion and Research’s Office of Compliance and Drug Short-
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
5 
•HR 3927 IH
age Program regarding the reviews of reports shared pur-
1
suant to section 704(b)(2), and any feedback or corrective 
2
or preventive actions in response to such reports.’’. 
3
(b) REPORTING.—Section 506C–1(a)(2) of the Fed-
4
eral Food, Drug, and Cosmetic Act (21 U.S.C. 356c– 
5
1(a)(2)) is amended to read as follows: 
6
‘‘(2)(A) describes the communication between 
7
the field investigators of the Food and Drug Admin-
8
istration and the staff of the Center for Drug Eval-
9
uation and Research’s Office of Compliance and 
10
Drug Shortage Program, including the Food and 
11
Drug Administration’s procedures for enabling and 
12
ensuring such communication; 
13
‘‘(B) provides the number of reports described 
14
in section 704(b)(2) that were required to be sent to 
15
the appropriate offices of the Food and Drug Ad-
16
ministration with expertise regarding drug shortage 
17
and the number of such reports that were sent; and 
18
‘‘(C) describes the adoption and utilization of 
19
the approach described in section 506D(g);’’. 
20
(c) APPLICABILITY.— 
21
(1) SUBSECTION (a).—The amendment made 
22
by subsection (a) shall apply beginning on the date 
23
of enactment of this Act. 
24
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
6 
•HR 3927 IH
(2) SUBSECTION (b).—The amendment made 
1
by subsection (b) shall apply beginning on the date 
2
that is 1 year after the date of enactment of this 
3
Act. 
4
SEC. 103. REPORTING OF MUTUAL RECOGNITION AGREE-
5
MENTS FOR INSPECTIONS AND REVIEW AC-
6
TIVITIES. 
7
(a) IN GENERAL.—Not later than the end of calendar 
8
year 2020, and annually thereafter, the Secretary of 
9
Health and Human Services (referred to in this section 
10
as the ‘‘Secretary’’) shall publish a report on the public 
11
website of the Food and Drug Administration on the utili-
12
zation of agreements entered into pursuant to section 809 
13
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
14
384e) or otherwise entered into by the Secretary to recog-
15
nize inspections between drug regulatory authorities 
16
across countries and international regions with analogous 
17
review criteria to the Food and Drug Administration, such 
18
as the Pharmaceutical Inspection Co-Operation Scheme, 
19
the Mutual Recognition Agreement with the European 
20
Union, and the Australia-Canada-Singapore-Switzerland 
21
Consortium, in the previous fiscal year. 
22
(b) CONTENT.—The report under subsection (a) shall 
23
include each of the following: 
24
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
7 
•HR 3927 IH
(1) The total number of establishments that are 
1
registered under section 510(i) of the Federal Food, 
2
Drug, and Cosmetic Act (21 U.S.C. 360(i)), and of 
3
such establishments, the number in each region of 
4
interest. 
5
(2) The total number of inspections conducted 
6
as described in subparagraphs (A) and (B) of para-
7
graph (5) at establishments described in paragraph 
8
(1). 
9
(3) Of the inspections described in paragraph 
10
(2), the total number of inspections in each of region 
11
of interest. 
12
(4) Of the inspections in each region of interest 
13
reported pursuant to paragraph (3), the number of 
14
inspections in each FDA inspection category. 
15
(5) Of the number of inspections reported 
16
under each of paragraphs (3) and (4)— 
17
(A) the number of inspections which have 
18
been conducted pursuant to an agreement or 
19
other recognition described in subsection (a); 
20
and 
21
(B) the number of inspections which have 
22
been conducted by employees or contractors of 
23
the Food and Drug Administration. 
24
(c) DEFINITIONS.—In this subsection: 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
8 
•HR 3927 IH
(1) FDA INSPECTION
CATEGORY.—The term 
1
‘‘FDA inspection category’’ means the following in-
2
spection categories: 
3
(A) Inspections to support approvals of 
4
changes to the manufacturing process of drugs 
5
approved under section 505 of the Federal 
6
Food, Drug, and Cosmetic Act (21 U.S.C. 355) 
7
or section 351 of the Public Health Service Act 
8
(42 U.S.C. 262). 
9
(B) Good manufacturing practice surveil-
10
lance inspections. 
11
(C) For-cause inspections. 
12
(2) REGION OF INTEREST.—The term ‘‘region 
13
of interest’’ means China, India, the European 
14
Union, and any other geographic region as the Sec-
15
retary determines appropriate. 
16
SEC. 104. ENHANCING TRANSPARENCY OF DRUG FACILITY 
17
INSPECTION TIMELINES. 
18
Section 902 of the FDA Reauthorization Act of 2017 
19
(21 U.S.C. 355 note) is amended to read as follows: 
20
‘‘SEC. 902. ANNUAL REPORT ON INSPECTIONS. 
21
‘‘Not later than March 1 of each year, the Secretary 
22
of Health and Human Services shall post on the public 
23
website of the Food and Drug Administration information 
24
related to inspections of facilities, including inspections 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
9 
•HR 3927 IH
that are necessary for approval of a drug under subsection 
1
(c) or (j) of section 505 of the Federal Food, Drug, and 
2
Cosmetic Act (21 U.S.C. 355), approval of a device under 
3
section 515 of such Act (21 U.S.C. 360e), or clearance 
4
of a device under section 510(k) of such Act (21 U.S.C. 
5
360(k)) that were conducted during the previous calendar 
6
year. Such information shall include the following: 
7
‘‘(1) The median time following a request from 
8
staff of the Food and Drug Administration review-
9
ing an application or report to the beginning of the 
10
inspection, including— 
11
‘‘(A) the median time for drugs described 
12
in section 505(j)(11)(A)(i) of the Federal Food, 
13
Drug, 
and 
Cosmetic 
Act 
(21 
U.S.C. 
14
355(j)(11)(A)(i)); 
15
‘‘(B) the median time for drugs described 
16
in section 506C(a) of such Act (21 U.S.C. 
17
356c(a)) only; and 
18
‘‘(C) the median time for drugs on the 
19
drug shortage list in effect under section 506E 
20
of such Act (21 U.S.C. 356f). 
21
‘‘(2) The median time from the issuance of a 
22
report pursuant to section 704(b) of such Act (21 
23
U.S.C. 374(b)) to the sending of a warning letter, 
24
issuance of an import alert, or holding of a regu-
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
10 
•HR 3927 IH
latory meeting for inspections for which the Sec-
1
retary concluded that regulatory or enforcement ac-
2
tion was indicated, including the median time for 
3
each category of drugs listed in subparagraphs (A) 
4
through (C) of paragraph (1). 
5
‘‘(3) The median time from the sending of a 
6
warning letter, issuance of an import alert, or hold-
7
ing of a regulatory meeting to resolution of the ac-
8
tions indicated to address the conditions or practices 
9
observed during an inspection. 
10
‘‘(4) The number of facilities that were unable 
11
to implement requested corrective or preventive ac-
12
tions following a report pursuant to such section 
13
704(b), resulting in a withhold recommendation, in-
14
cluding the number of such times for each category 
15
of drugs listed in subparagraphs (A) through (C) of 
16
paragraph (1).’’. 
17
SEC. 105. ADVANCED MANUFACTURING TECHNOLOGIES 
18
PROGRAM. 
19
Subchapter A of chapter V of the Federal Food, 
20
Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend-
21
ed by adding at the end the following: 
22
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
11 
•HR 3927 IH
‘‘SEC. 524B. ADVANCED MANUFACTURING TECHNOLOGIES 
1
PROGRAM. 
2
‘‘(a) IN GENERAL.—Not later than 1 year after the 
3
date of enactment of the Manufacturing API, Drugs, and 
4
Excipients in America Act, the Secretary shall continue 
5
in effect the programs to facilitate the development and 
6
review of an application under subsection (b) or (j) of sec-
7
tion 505 of this Act or subsection (a) or (k) of section 
8
351 of the Public Health Service Act for a drug or biologi-
9
cal product that is manufactured using one of more ad-
10
vanced manufacturing technologies that have been des-
11
ignated in accordance with subsection (b). 
12
‘‘(b) DESIGNATION.—The Secretary shall designate a 
13
method of manufacturing or development of a drug or bio-
14
logical product as an advanced manufacturing technology 
15
under this section if it incorporates a novel technology or 
16
uses an established technique or technology in a novel way 
17
that— 
18
‘‘(1) enhances drug quality; or 
19
‘‘(2) improves the flexibility, robustness, or effi-
20
ciency of the manufacturing process to— 
21
‘‘(A) prevent or resolve a drug shortage; 
22
‘‘(B) reduce premarket development time; 
23
or 
24
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
12 
•HR 3927 IH
‘‘(C) increase the supply of drugs described 
1
in paragraph (1) or (2) of section 506C(a) for 
2
national emergencies. 
3
‘‘(c) CONSULTATION.—If the Secretary designates a 
4
method of manufacturing as an advanced manufacturing 
5
technology under this section, the Secretary shall take ac-
6
tions to expedite the development and implementation of 
7
such method of manufacture for purposes of approval of 
8
an application under subsection (c) or (j) of section 505 
9
of this Act or subsection (a) or (k) of section 351 of the 
10
Public Health Service Act, which may include, as appro-
11
priate, holding meetings between the sponsor of the appli-
12
cation and appropriate Food and Drug Administration 
13
staff throughout the development of the drug of biological 
14
product using such advanced manufacturing technology. 
15
‘‘(d) EVALUATION
OF
AN ADVANCED MANUFAC-
16
TURING TECHNOLOGY.— 
17
‘‘(1) PACKAGE.—A person who seeks designa-
18
tion of an advanced manufacturing technology under 
19
this section shall submit to the Secretary a package 
20
of scientific evidence supporting the implementation 
21
of the advanced manufacturing technology in a par-
22
ticular context-of-use. The Secretary shall assist 
23
with the development of such package by— 
24
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
13 
•HR 3927 IH
‘‘(A) providing timely advice to, and inter-
1
active communication with, the sponsor regard-
2
ing the development of the technology; and 
3
‘‘(B) involving senior managers and experi-
4
enced staff of the Food and Drug Administra-
5
tion, as appropriate, in a collaborative, cross- 
6
disciplinary review of the method of manufac-
7
turing. 
8
‘‘(2) EVALUATION.—Within 90 days of receiv-
9
ing a package under paragraph (1), the Secretary 
10
shall determine whether a designated advanced man-
11
ufacturing technology is validated for the proposed 
12
context of use based on the scientific merit the sup-
13
porting evidence provided by the sponsor. 
14
‘‘(3) EFFECT
OF
DESIGNATION.—Upon des-
15
ignation of an advanced manufacturing technology, 
16
the holder of the advanced manufacturing technology 
17
designation, or a person the advanced manufac-
18
turing technology designation holder authorizes, may 
19
rely upon the advanced manufacturing technology 
20
for use across multiple manufacturing or product 
21
lines within the same context-of-use without having 
22
to re-submit data to the Secretary validating the un-
23
derlying technology. 
24
‘‘(e) IMPLEMENTATION AND REPORTING.— 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
14 
•HR 3927 IH
‘‘(1) PUBLIC
MEETING.—The Secretary shall 
1
publish in the Federal Register a notice of a public 
2
meeting, to be held not later than 1 year after the 
3
date of enactment of the Manufacturing API, 
4
Drugs, and Excipients in America Act, to discuss 
5
and obtain input and recommendations from stake-
6
holders regarding the goals and scope of, and a suit-
7
able framework and procedures and requirements 
8
for, the program under this section. 
9
‘‘(2) 
PROGRAM
GUIDANCE.—The 
Secretary 
10
shall— 
11
‘‘(A) not later than 1 year after the date 
12
of enactment of the Manufacturing API, Drugs, 
13
and Excipients in America Act, issue draft 
14
guidance regarding the goals and implementa-
15
tion of the program under this section; and 
16
‘‘(B) not later than 2 years after the date 
17
of enactment of the Manufacturing API, Drugs, 
18
and Excipients in America Act, issue final guid-
19
ance with respect to the implementation of such 
20
program. 
21
‘‘(3) REPORT.—The Secretary shall make avail-
22
able on the public website of the Food and Drug Ad-
23
ministration an annual report on the progress of the 
24
programs under this section.’’. 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
15 
•HR 3927 IH
TITLE II—TAX INCENTIVES TO 
1
INCREASE DOMESTIC PHAR-
2
MACEUTICAL AND MEDICAL 
3
DEVICE PRODUCTION 
4
SEC. 201. CREDIT FOR PHARMACEUTICAL AND MEDICAL 
5
DEVICE PRODUCTION ACTIVITIES IN DIS-
6
TRESSED ZONES. 
7
(a) IN GENERAL.—Subpart D of part IV of sub-
8
chapter A of chapter 1 of the Internal Revenue Code of 
9
1986 is amended by adding at the end the following new 
10
section: 
11
‘‘SEC. 45U. DISTRESSED ZONE PHARMACEUTICAL AND MED-
12
ICAL DEVICE PRODUCTION CREDIT. 
13
‘‘(a) IN GENERAL.—For purposes of section 38, the 
14
distressed zone pharmaceutical and medical device produc-
15
tion credit for the taxable year shall be an amount equal 
16
to the applicable percentage of the qualified production ac-
17
tivity expenditures of the taxpayer for the taxable year. 
18
‘‘(b) APPLICABLE PERCENTAGE.—For purposes of 
19
this section— 
20
‘‘(1) IN GENERAL.—Except as provided in para-
21
graph (2), the term ‘applicable percentage’ means 
22
25 percent. 
23
‘‘(2) INCREASED AMOUNT WHERE EMPLOYEES 
24
RESIDE IN DISTRESSED ZONE.—In the case of any 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
16 
•HR 3927 IH
qualified pharmaceutical or medical device produc-
1
tion business a substantial portion of the employees 
2
of which reside in a distressed zone, the applicable 
3
percentage shall be 30 percent. 
4
‘‘(c) QUALIFIED PRODUCTION ACTIVITY EXPENDI-
5
TURES.—For purposes of this section— 
6
‘‘(1) IN GENERAL.—The term ‘qualified produc-
7
tion activity expenditures’ means— 
8
‘‘(A) wages paid or incurred to an em-
9
ployee of the taxpayer for services performed by 
10
such employee in the conduct of a qualified 
11
pharmaceutical or diagnostic medical device 
12
production business in a distressed zone (but 
13
only if the employee’s principal place of employ-
14
ment is in a distressed zone), and 
15
‘‘(B) qualified pharmaceutical or medical 
16
device production expenditures. 
17
‘‘(2) QUALIFIED PHARMACEUTICAL OR MEDICAL 
18
DEVICE PRODUCTION BUSINESS.— 
19
‘‘(A) IN
GENERAL.—The term ‘qualified 
20
pharmaceutical or medical device production 
21
business’ means the trade or business of pro-
22
ducing qualified pharmaceuticals in commercial 
23
quantities. 
24
‘‘(B) QUALIFIED PHARMACEUTICALS.— 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
17 
•HR 3927 IH
‘‘(i) IN GENERAL.—The term ‘quali-
1
fied 
pharmaceuticals’ 
means 
pharma-
2
ceuticals, active pharmaceutical ingredi-
3
ents, excipients, medical diagnostic devices, 
4
or personal protective equipment. 
5
‘‘(ii) PHARMACEUTICAL.—The term 
6
‘pharmaceuticals’— 
7
‘‘(I) means any drug (as defined 
8
in section 201 of the Federal Food, 
9
Drug, and Cosmetic Act), and 
10
‘‘(II) includes a biological prod-
11
uct (as defined in section 351 of the 
12
Public Health Service Act). 
13
‘‘(iii) ACTIVE
PHARMACEUTICAL
IN-
14
GREDIENT.—The term ‘active pharma-
15
ceutical ingredients’ has the meaning given 
16
to such term in section 207.1 of title 21, 
17
Code of Federal Regulations (or any suc-
18
cessor regulations). 
19
‘‘(iv) EXCIPIENT.—The term ‘excip-
20
ient’— 
21
‘‘(I) means any inactive ingre-
22
dient that is intentionally added to a 
23
pharmaceutical that is not intended to 
24
exert therapeutic effects at the in-
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
18 
•HR 3927 IH
tended dosage, other than by acting to 
1
improve product delivery, and 
2
‘‘(II) includes any such filler, ex-
3
tenders, diluent, wetting agent, sol-
4
vent, emulsifier, preservative, flavor, 
5
absorption enhancer, sustained release 
6
matrix, and coloring agent. 
7
‘‘(v) MEDICAL DIAGNOSTIC DEVICE.— 
8
The term ‘medical diagnostic device’ means 
9
any device (as defined in section 201(h) of 
10
the Federal Food, Drug, and Cosmetic 
11
Act) intended for use in the diagnosis of 
12
disease or other conditions. 
13
‘‘(vi) PERSONAL PROTECTIVE EQUIP-
14
MENT.—The 
term 
‘personal 
protective 
15
equipment’ means— 
16
‘‘(I) any device (as defined in 
17
section 201(h) of the Federal Food, 
18
Drug, and Cosmetic Act) that is a 
19
face mask, filtering facepiece res-
20
pirator, face shield, surgical mask, 
21
gown, other apparel, or glove that is 
22
intended for a medical purpose, and 
23
‘‘(II) any particulate filtering air 
24
purifying respiratory protective device 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
19 
•HR 3927 IH
that is approved by the National In-
1
stitute for Occupational Safety and 
2
Health under part 84 of title 42, Code 
3
of Federal Regulations (or successor 
4
regulations). 
5
‘‘(3) CERTAIN HEALTH PLAN EXPENSES TREAT-
6
ED AS WAGES.— 
7
‘‘(A) IN
GENERAL.—The term ‘wages’ 
8
shall include so much of the eligible employer’s 
9
qualified health plan expenses as are properly 
10
allocable to such wages. 
11
‘‘(B) 
QUALIFIED
HEALTH
PLAN
EX-
12
PENSES.—For purposes of this paragraph, the 
13
term ‘qualified health plan expenses’ means 
14
amounts paid or incurred by the eligible em-
15
ployer to provide and maintain a group health 
16
plan (as defined in section 5000(b)(1)), but 
17
only to the extent that such amounts are ex-
18
cluded from the gross income of employees by 
19
reason of section 106(a) of such Code. 
20
‘‘(C) ALLOCATION RULES.—For purposes 
21
of this paragraph, qualified health plan ex-
22
penses shall be allocated to qualified wages in 
23
such manner as the Secretary may prescribe. 
24
Except as otherwise provided by the Secretary, 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
20 
•HR 3927 IH
such allocation shall be treated as properly 
1
made if made on the basis of being pro rata 
2
among employees and pro rata on the basis of 
3
periods of coverage (relative to the periods to 
4
which such wages relate). 
5
‘‘(4) QUALIFIED PHARMACEUTICAL OR MEDICAL 
6
DEVICE PRODUCTION EXPENDITURES.— 
7
‘‘(A) DEFINITION.—The term ‘qualified 
8
pharmaceutical or medical device production ex-
9
penditures’ means amount paid or incurred 
10
(whether or not chargeable to capital account) 
11
for qualified property used in the conduct of a 
12
qualified pharmaceutical or medical device pro-
13
duction business in a distressed zone (but only 
14
if the primary use of such property is in a dis-
15
tressed zone). 
16
‘‘(B) QUALIFIED PROPERTY.— 
17
‘‘(i) IN GENERAL.—The term ‘quali-
18
fied property’ means any tangible personal 
19
property (other than a building or its 
20
structural components) used in the conduct 
21
of a qualified pharmaceutical or medical 
22
device production business in a distressed 
23
zone (but only if the primary use of such 
24
property is in a distressed zone). 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
21 
•HR 3927 IH
‘‘(ii) EXCEPTION.—Such term shall 
1
not include any property described in sec-
2
tion 50(b) (determined as if the United 
3
States included Puerto Rico). 
4
‘‘(d) DISTRESSED ZONE.—For purposes of this sec-
5
tion, the term ‘distressed zone’ means a population census 
6
tract which— 
7
‘‘(1) has been designated as a qualified oppor-
8
tunity zone under section 1400Z–1, and 
9
‘‘(2) has a poverty rate in excess of 30 percent 
10
for the calendar year prior to the calendar year that 
11
includes the date of enactment of this section. 
12
‘‘(e) SPECIAL RULES.— 
13
‘‘(1) APPLICATION TO UNITED STATES SHARE-
14
HOLDERS
OF
CONTROLLED
FOREIGN
CORPORA-
15
TIONS.— 
16
‘‘(A) IN GENERAL.—In the case of a do-
17
mestic corporation that is a United States 
18
shareholder of a qualified controlled foreign cor-
19
poration, the credit under subsection (a) (deter-
20
mined without regard to this paragraph) shall 
21
be increased by an amount equal to 30 percent 
22
of the corporation’s pro rata share (determined 
23
under rules similar to the rules of section 
24
951(a)(2)) of qualified production activity ex-
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
22 
•HR 3927 IH
penditures of such controlled foreign corpora-
1
tion for the taxable year of the qualified con-
2
trolled foreign corporation ending with or with-
3
in the taxable year of the domestic corporation. 
4
‘‘(B) QUALIFIED CORPORATION.—For pur-
5
poses of subparagraph (A), the term ‘qualified 
6
controlled foreign corporation’ means, for any 
7
taxable year, a controlled foreign corporation 
8
which does not have gross income that is effec-
9
tively connected with the conduct of a trade or 
10
business within the United States for such tax-
11
able year. 
12
‘‘(2) REDUCTION IN BASIS.—If a credit is de-
13
termined under this section with respect to any 
14
property by reason of any qualified production activ-
15
ity expenditures described in subsection (b)(1)(B), 
16
the basis of such property shall be reduced by the 
17
amount of the credit so determined. 
18
‘‘(3) COORDINATION WITH OTHER CREDITS.— 
19
Any qualified production activity expenditures taken 
20
into account in determining the amount of the credit 
21
under subsection (a) shall not be taken into account 
22
in determining a credit under any other provision of 
23
this chapter. 
24
‘‘(f) RECAPTURE.— 
25
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
23 
•HR 3927 IH
‘‘(1) IN GENERAL.—If, during any taxable year, 
1
property 
take 
into 
account 
under 
subsection 
2
(c)(1)(B) is disposed of, or otherwise ceases to be 
3
used by the taxpayer in the active trade or business 
4
of producing qualified pharmaceuticals in commer-
5
cial quantities, before the close of the recapture pe-
6
riod, then the tax under this chapter for such tax-
7
able year shall be increased by the recapture per-
8
centage of the aggregate decrease in the credits al-
9
lowed under section 38 for all prior taxable years 
10
which would have resulted solely from reducing to 
11
zero any credit determined under this section with 
12
respect to such property. 
13
‘‘(2) RECAPTURE PERCENTAGE.—For purposes 
14
of subparagraph (A), the recapture percentage shall 
15
be determined in the same manner as under section 
16
50(a)(1)(B). 
17
‘‘(3) APPLICATION TO UNITED STATES SHARE-
18
HOLDERS.—In the case of any taxpayer to whom a 
19
credit is allowed by reason of subsection (e)(1), 
20
paragraph (1) shall be applied by substituting ‘the 
21
controlled foreign corporation with respect to which 
22
the taxpayer is a United States shareholder’ for ‘the 
23
taxpayer’. 
24
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
24 
•HR 3927 IH
‘‘(4) APPLICATION
OF
OTHER
RULES.—For 
1
purposes of this paragraph, rules similar to the rules 
2
of paragraphs (3), (4), and (5) (other than subpara-
3
graph (A) thereof) of section 50(a)(1) shall apply.’’. 
4
(b) CREDIT ALLOWED AGAINST ALTERNATIVE MIN-
5
IMUM TAX.—Section 38(c)(4)(B) of such Code is amended 
6
by redesignating clauses (x), (xi), and (xii) as clauses (xi), 
7
(xii), and (xiii), respectively, and by inserting after clause 
8
(ix) the following new clause: 
9
‘‘(x) the credit determined under sec-
10
tion 45U,’’. 
11
(c) CREDIT ALLOWED AGAINST BASE EROSION 
12
ANTI-ABUSE
TAX.—Section 59A(b)(1)(B)(ii) of such 
13
Code is amended by striking ‘‘plus’’ at the end of sub-
14
clause (I), by redesignating subclause (II) as subclause 
15
(III), and by inserting after subclause (I) (as so amended) 
16
the following new subclause: 
17
‘‘(II) the credit allowed under 
18
section 38 for the taxable year which 
19
is properly allocable to the distressed 
20
zone pharmaceutical and medical de-
21
vice 
production 
credit 
determined 
22
under section 45U(a), plus’’. 
23
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
25 
•HR 3927 IH
(d) DENIAL OF DEDUCTION.—Section 280C of such 
1
Code is amended by adding at the end the following new 
2
subsection: 
3
‘‘(i) DISTRESSED
ZONE
PHARMACEUTICAL
AND 
4
MEDICAL DEVICE PRODUCTION CREDIT.—No deduction 
5
shall be allowed for that portion of the qualified produc-
6
tion activity expenditures (as defined in section 45U(b)) 
7
otherwise allowable as a deduction for the taxable year 
8
which is equal to the amount of the distressed zone phar-
9
maceutical and medical device production credit deter-
10
mined for such taxable year under section 45U(a).’’. 
11
(e) PART OF GENERAL BUSINESS CREDIT.—Section 
12
38(b) of such Code is amended by striking ‘‘plus’’ at the 
13
end of paragraph (32), by striking the period at the end 
14
of paragraph (33) and inserting ‘‘, plus’’, and by adding 
15
at the end the following new paragraph: 
16
‘‘(34) the distressed zone pharmaceutical and 
17
medical device production credit determined under 
18
section 45U(a).’’. 
19
(f) CLERICAL AMENDMENT.—The table of sections 
20
for subpart D of part IV of subchapter A of chapter 1 
21
is amended by adding at the end the following new item: 
22
‘‘Sec. 45U. Distressed zone pharmaceutical and medical device production cred-
it.’’. 
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
26 
•HR 3927 IH
(g) EFFECTIVE DATE.—The amendments made by 
1
this section shall apply to amounts paid or incurred after 
2
the date of the enactment of this Act. 
3
Æ 
01:29 Jul 16, 2021
H3927
ctelli on DSK11ZRN23PROD with BILLS
